Medindia

X

Avastinís Future in FDAís Hands

by Savitha C Muppala on  March 4, 2011 at 3:31 PM Cancer News   - G J E 4
Avastin, the wonder drug which has been the last resort for many women suffering metastatic breast cancer, risked being disapproved by the FDA last December. Obviously, this is not good news for many advance-stage breast cancer patients.
 Avastinís Future in FDAís Hands
Avastinís Future in FDAís Hands
Advertisement

Nearly 17,500 women rely on Avastin, an advanced stage breast cancer drug that helps reduce blood flow to tumors , thus slowing their growth, and even completely wiping out the tumors in some cases. Therefore, the drug helps women survive much longer.

Advertisement
Avastin is expensive and patients need to spend more than $90,000 a year on treatment.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All